MicroIslet diabetic primate study shows decreased need for insulin

By Elaine Rigoli

Tampa, Fla., Aug. 7 - MicroIslet, Inc. said that during a six-month period, primate subjects showed substantial reduction in the need for insulin to control blood glucose levels by means of MicroIslet's proprietary microencapsulated porcine islet transplantation treatment approach.

Additionally, the company said this breakthrough was achieved without the need for chronic immunosuppressive therapy to prevent rejection of the transplanted insulin-producing islets.

"We believe that with this positive data, we are setting the cornerstone for a new and vastly improved treatment for diabetes, which has reached an epidemic stage, afflicting an estimated 21 million Americans, including over 6 million who are undiagnosed," president and chief executive officer James R. Gavin III said in a news release.

The transplantation site in the peritoneum allows a minimally invasive procedure, substantially decreasing the risks inherent in major surgery, the release said.

The company added that it has secured access to a sufficient supply of islet tissues for human clinical trials and eventual commercialization of its diabetes treatment approach through a long-term islet supply agreement with the Mayo Foundation for Medical Education and Research.

MicroIslet is a biotechnology company with headquarters in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.